SecBot SecBot

NAMS

NewAmsterdam Pharma Co N.V.
Nasdaq· Pharmaceutical Preparations· Inc. P7· CIK 0001936258 Biotech & Drug Discovery
$19.46 −0.68 (−3.38%)
Nov 16 4:00 PM ET · prev $20.14
Market cap
$2.4B
Mid cap
Consensus
Buy
91% Buy or better · 23 analysts
Median target
🔒 Subscribers only
1 year
−49.5%
from $38.56 · Nov 17
30 days
−4.9%
from $20.47
52-week range
$18.89–41.45
−53% from high · low Nov 5
Avg volume 20D
1.81M
shares / day
Short interest
12.01M
≈10.0% of shares · −14.9%
Days to cover
8.3
at average volume
Insider net
−$46.0M
1 buyer · 5 sellers · 12 mo
New fund stakes
1
Q3 2026 13F · 2 exits
Filing reports
8
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 2 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $226.5K at an average $22.65. 5 insiders sold $46.2M. Price is 14% below their cost.

  • InstitutionsMIXED

    Q3 2026: 21 added (1 new), 17 trimmed or exited.

  • AnalystsBULLISH

    21 of 23 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −14.9% to 12.01M shares. 8.3 days to cover, ≈10.0% of shares.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
2
exits
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCADD865,403$21.0M
MORGAN STANLEYADD836,582$20.3M
Qube Research & Technologies LtdDOUBLED373,272$9.1M
Jump Financial, LLCDOUBLED357,521$8.7M
JANE STREET GROUP, LLCTRIM345,720$8.4M
VICTORY CAPITAL MANAGEMENT INCADD308,835$7.5M
BARCLAYS PLCDOUBLED280,411$6.8M
HRT FINANCIAL LPTRIM225,079$5.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 91% rate it Buy or better
Strong Buy9Buy12Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 11, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Nov 5, 2026Needham
MAINTAIN
MAINTAINBuy
Oct 5, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Sep 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 6, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Jun 30, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$226.5K
bought · 1 insider
$46.2M
sold · 5 insiders
−14.1%
vs their $22.65 cost
DateInsiderTypeValue
Sep 30, 2026
Kastelein Johannes Jacob Pieter
Chief Scientific Officer
Sep 30, 2026
EXERCISE50,246 sh
Sep 30, 2026
Kastelein Johannes Jacob Pieter
Chief Scientific Officer
Sep 30, 2026
SELL$1.3M
Sep 14, 2026
Davidson Michael H.
Chief Executive Officer
Sep 14, 2026
BUY$226.5K
Sep 4, 2026
Smither John W
Director
Sep 4, 2026
SELL$40.5K
Sep 1, 2026
Gunning Robert William
Vice President, Controller
Sep 1, 2026
AWARD14,000 sh
Sep 1, 2026
Gunning Robert William
Vice President, Controller
Sep 1, 2026
AWARD3,200 sh
Jul 20, 2026
Kooij Louise Frederika
Chief Accounting Officer
Jul 20, 2026
EXERCISE$893.6K
Jul 20, 2026
Kooij Louise Frederika
Chief Accounting Officer
Jul 20, 2026
EXERCISE$297.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
12,009,626
shares short
-14.9%
vs prior settlement
8.3
days to cover
≈10.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 11, 2026 Earnings calendar
NAMS Q3 2026 Earnings Before Market Open · 2026-11-11
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 11,941,763 common shares of…
SC 13G/A · Impact 2/10
Nov 4, 2026 SEC
NewAmsterdam Pharma reported Q3 2026 net loss of $17.4M, significantly narrower than the $72.0M loss in Q3 2025…
PRESS-RELEASE · Impact 5/10
Sep 30, 2026 Insider
Kastelein Johannes Jacob Pieter acquired via exercise 50,246 shares
Chief Scientific Officer
Sep 30, 2026 Insider
Kastelein Johannes Jacob Pieter sold 50,246 shares
Chief Scientific Officer @ $25.03 ($1.3M)
Sep 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC · ADD
865,403 shares ($21.0M)
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
836,582 shares ($20.3M)
Sep 29, 2026 SEC
NewAmsterdam Pharma announced the dosing of the first patient in SPINOZA, a Phase 2b trial evaluating obicetrapib in…
8-K · Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 11, 2026
Earnings date
NAMS Q3 2026 Earnings Before Market Open · 2026-11-11
Nov 6, 2026
Press release
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the…
Nov 4, 2026
Earnings
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination)…
Oct 15, 2026
Short interest
Short Interest: NAMS down 26% to 14.1M shares
Settlement 2026-10-15 | Days to cover: 10.64 | ≈11.80% of shares outstanding (est.)
Oct 2, 2026
Press release
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the…

SecBot reports

8 filings · 4 bullish · 0 bearish · 4 neutral
All NAMS filing & press-release reports (8)